Elanco Animal Health Inc. - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Elanco Animal Health Inc. is a global leader in animal health, operating as a single segment focused on pet health and farm animal products. The company is a large accelerated filer with approximately 496.8 million shares of common stock outstanding as of August 4, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $1,241 million | $1,184 million | $2,434 million | $2,389 million |
| Gross Profit | $713 million | $689 million | $1,397 million | $1,379 million |
| Gross Margin | 57% | 58% | 57% | 58% |
| Net Income (Loss) | $11 million | ($50 million) | $78 million | ($18 million) |
| Diluted EPS | $0.02 | ($0.10) | $0.16 | ($0.04) |
| Operating Cash Flow (YTD) | $233 million (2025) vs $202 million (2024) | |||
| Total Debt (Long-term + Current) | $4,209 million (as of June 30, 2025) | |||
| Cash and Equivalents | $539 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability in Q2 2025 ($11M net income) compared to a net loss of $50M in Q2 2024. This improvement was driven by a significant reduction in special charges and lower interest expense.
- Revenue Growth: Revenue increased 5% year-over-year in Q2 2025. Pet Health revenue grew 11% due to volume increases from new products (Credelio Quattro, Zenrelia, AdTab) and pricing. Farm Animal revenue declined 2% primarily due to the prior-year divestiture of the Aqua business.
- Special Charges: Asset impairment, restructuring, and other special charges dropped 99% to $1 million in Q2 2025 from $80 million in Q2 2024. The prior year included a $53 million impairment of an IPR&D asset and transaction costs related to the Aqua divestiture.
- Interest Expense: Net interest expense decreased 26% to $48 million, driven by lower average debt balances following debt paydowns, partially offset by $7 million in imputed interest on a new liability for the sale of future revenue.
- Divestiture Impact: The Aqua business, sold in July 2024, contributed $49 million in revenue in Q2 2024 but $0 in Q2 2025.
Guidance, Outlook, and Risks
- Product Launches: Management highlights successful launches of Zenrelia (approved in EU in July 2025), Credelio Quattro, and AdTab as key drivers for Pet Health growth. Bovaer (methane-reducing feed) began commercial use in the U.S. in late 2024.
- Trade Environment: New tariffs in 2025 have led to accelerated customer purchases in international farm animal markets (notably China) in anticipation of future costs. While pharmaceutical products are largely exempt from recent U.S. tariffs, the company is monitoring global trade policies closely.
- Capital Allocation: In May 2025, Elanco sold future royalty rights to Blackstone for $295 million, recorded as a liability, to repay term loan debt. In June 2025, the company commenced a $255 million finance lease for its new corporate headquarters in Indianapolis.
- Tax Legislation: The "One Big Beautiful Bill Act" enacted on July 4, 2025, includes tax cut extensions. Elanco is evaluating the impact on its valuation allowance and consolidated results.
- Legal Risks: The company is defending multiple shareholder derivative actions and a securities class action (Barpar) alleging misstatements regarding product safety and launch timelines. Additionally, follow-on litigation related to the Tevra antitrust case remains pending.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of Pet Health volume growth post-initial stocking of new products like Credelio Quattro and Zenrelia.
- Debt Structure: Review the terms of the $295 million "Liability for Sale of Future Revenue" and the impact of the 16.1% effective interest rate on future earnings.
- Margin Pressure: Assess the long-term impact of inflation and the higher manufacturing costs associated with the re-acquired Speke facility on gross margins.
- Legal Exposure: Monitor the status of the Barpar securities class action and derivative suits, as well as the appeal in the Tevra antitrust matter.
- Trade Policy: Evaluate the potential impact of retaliatory tariffs and the removal of government incentives for sustainability products on Farm Animal revenue.